Bilirubin/Albumin Ratio (BAR Index): Explanation and Clinical Context The Bilirubin/Albumin Ratio (BAR) is a biochemical marker that reflects the balance between liver excretory function (represented by serum bilirubin) and synthetic capacity (represented by albumin). An elevated BAR value indicates an imbalance between hepatocellular injury and decreased albumin synthesis, both of which are associated with systemic inflammation and poor clinical outcomes.
Originally introduced as a prognostic index in acute-on-chronic liver failure, the BAR Index has shown strong predictive value for in-hospital mortality and short-term prognosis. Subsequent studies have validated its utility in patients with sepsis, heart failure, and other critical conditions, where it correlates with disease severity, multi-organ dysfunction, and overall mortality risk.
Typical clinical interpretation:
• BAR < 0.3 → Low risk (usually compensated liver or mild systemic dysfunction)
• BAR 0.3–0.7 → Intermediate risk (moderate dysfunction or stress response)
• BAR > 0.7 → High risk (significant liver impairment, inflammation, or multiorgan failure)
Clinical Significance
BAR integrates two key prognostic parameters into a simple ratio that is both cost-effective and widely available in clinical practice. It allows early identification of high-risk patients who may benefit from intensive monitoring, advanced therapies, or timely intervention.
Reference:
Wang L, et al. "Bilirubin/Albumin Ratio as a Prognostic Indicator in Patients with Liver Dysfunction: A Retrospective Cohort Study." Clin Chim Acta. 2021;517:9–16. doi:10.1016/j.cca.2021.02.024